Daiichi Sankyo, Inc. has entered into a strategic agreement with Syneos Health to form a coalition to bring promising cancer therapies to patients, safely, and efficiently.   Syneos Health will provide strategic and operational services for three lead Daiichi antibody drug conjugates (ADC):  DS-1062, U3-1402 and DS-8201 (known as ENHERTU). The coalition expands a pre-existing relationship between the companies, further leveraging Syneos Health’s Syneos One product development model to de-risk ...